In Deals With Respivert And Orexo, J&J's Respiratory Push Gets Going
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J acquired respiratory drug discovery firm Respivert and licensed two respiratory preclinical research programs from Orexo.